Status and phase
Conditions
Treatments
About
Compare the efficacy and safety of Orelabrutinib plus bendamustine+ rituximab versus bendamustine + rituximab in previously untreated patients with mantle cell lymphoma (MCL)
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
490 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
Alexia Lu
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal